Introduction The management of patients with residual masses following chemotherapy for advanced seminoma remains a difficult problem with no clear guidelines. While most patients with advanced seminoma achieve a complete or partial response with cisplatin based chemotherapy1, a significant number will reveal a residual mass on follow up CT scan or MR imaging2,3. Management options for post chemotherapy residual mass in a case of seminoma include close observation, radiation therapy and excisional surgery. While 80 to 85% of residual masses represent either fibrosis or necrotic tissue needing no further therapy, 10 to 15% may contain viable tumor which, if not recognized and effectively treated, may be lethal. A case of a stage II seminoma ...
Germ cell tumors of the testes represent a unique paradigm of diseases which can be cured even in ex...
Background: After chemotherapy for nonseminomatous testicular germ cell tumor (NSTGCT), residual mas...
Background: After chemotherapy for nonseminomatous testicular germ cell tumor (NSTGCT), residual mas...
Introduction The management of patients with residual masses following chemotherapy for advanced sem...
Introduction The management of patients with residual masses following chemotherapy for advanced sem...
Introduction The management of patients with residual masses following chemotherapy for advanced sem...
Introduction The management of patients with residual masses following chemotherapy for advanced sem...
Thirty-six patients with advanced seminoma treated with cisplatin combination chemotherapy were eval...
Purpose: Guidelines for management of postchemo-therapy residual mass in patients with advanced semi...
Treatment for metastatic testicular tumors is based on risk stratification according to Internationa...
Advanced stage nonseminomatous testis cancer is commonly treated with chemotherapy and surgical rese...
The basis of treatment for advanced germ cell tumors is chemotherapy and surgical resection of resid...
Purpose Residual lesions after chemotherapy are frequent in metastatic seminoma. Watchful waiting is...
PURPOSE: to determine the role of RPLND for residual masses following chiotherapy in patients with n...
PURPOSE Residual lesions after chemotherapy are frequent in metastatic seminoma. Watchful waiting...
Germ cell tumors of the testes represent a unique paradigm of diseases which can be cured even in ex...
Background: After chemotherapy for nonseminomatous testicular germ cell tumor (NSTGCT), residual mas...
Background: After chemotherapy for nonseminomatous testicular germ cell tumor (NSTGCT), residual mas...
Introduction The management of patients with residual masses following chemotherapy for advanced sem...
Introduction The management of patients with residual masses following chemotherapy for advanced sem...
Introduction The management of patients with residual masses following chemotherapy for advanced sem...
Introduction The management of patients with residual masses following chemotherapy for advanced sem...
Thirty-six patients with advanced seminoma treated with cisplatin combination chemotherapy were eval...
Purpose: Guidelines for management of postchemo-therapy residual mass in patients with advanced semi...
Treatment for metastatic testicular tumors is based on risk stratification according to Internationa...
Advanced stage nonseminomatous testis cancer is commonly treated with chemotherapy and surgical rese...
The basis of treatment for advanced germ cell tumors is chemotherapy and surgical resection of resid...
Purpose Residual lesions after chemotherapy are frequent in metastatic seminoma. Watchful waiting is...
PURPOSE: to determine the role of RPLND for residual masses following chiotherapy in patients with n...
PURPOSE Residual lesions after chemotherapy are frequent in metastatic seminoma. Watchful waiting...
Germ cell tumors of the testes represent a unique paradigm of diseases which can be cured even in ex...
Background: After chemotherapy for nonseminomatous testicular germ cell tumor (NSTGCT), residual mas...
Background: After chemotherapy for nonseminomatous testicular germ cell tumor (NSTGCT), residual mas...